ImmunoPrecise Antibodies Ltd. Advances Universal Dengue Vaccine Initiative to Preclinical Manufacturing Stage
ImmunoPrecise Antibodies Ltd. has advanced its universal dengue vaccine initiative to the preclinical manufacturing stage, focusing on in vivo testing and virus neutralization analysis. This follows the validation of a conserved dengue epitope using their LENSai™ platform and HYFT® technology. The vaccine candidate will be tested using proprietary immunization protocols at their Canadian facility, with results pending. This marks a significant step in their translational development efforts across infectious diseases.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) has announced a significant advancement in its universal dengue vaccine program, marking a transition to pre-clinical manufacturing for in vivo testing and virus neutralization analysis. This development follows their earlier discovery and validation of a conserved dengue epitope using the LENSai™ platform and HYFT® technology. The manufactured vaccine candidate will undergo proprietary immunization protocols at the company’s Canadian facility, utilizing a rabbit model to evaluate monoclonal antibody responses. This step is crucial for translational development. The results of these immunization studies are yet to be presented, as the company moves from AI discovery to live immunization studies, aiming to demonstrate the potential of their platform across infectious diseases. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImmunoPrecise Antibodies Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250827492115) on August 27, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
